Skip to main content
●+254 119 023975 support@dnalabskenya.com
Patient Portal LoginB2B / Doctor Portal
DNA LabsKenya
Medical information Clinical review pending

Genetic Testing

Nras Mutation Codon 12 13 61 Test

The NRAS Mutation Codon 12 13 61 Test identifies specific mutations in the NRAS gene, aiding in cancer diagnosis and personalized treatment planning, particularly for melanoma and colorectal cancer.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Formalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue.
Results
Confirm with the laboratory before booking.
Preparation
No patient preparation is required. Ensure the FFPE tissue block is accompanied by a completed NGS Test Requisition Form (Form 40). Confirm with the laboratory before booking.
Test priceKSh 17,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Nras Mutation Codon 12 13 61 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us
01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients diagnosed with melanoma.
  • ✓Patients diagnosed with colorectal cancer.
  • ✓Individuals with suspected cancer where NRAS mutation status is relevant.
  • ✓Patients whose cancer may benefit from targeted therapies based on NRAS status.
02

In plain language

What this test helps you understand

This test helps identify specific mutations in the NRAS gene that can influence cancer behavior and response to therapy, guiding personalized treatment decisions for certain types of cancer.
The NRAS Mutation Codon 12 13 61 Test is a diagnostic tool used in oncology to detect mutations within the NRAS gene. These mutations are linked to the development and progression of certain cancers, such as melanoma and colorectal cancer. Identifying these specific mutations helps doctors understand the potential behavior of the cancer and guide treatment decisions. This test focuses on codons 12, 13, and 61 of the NRAS gene. The results can provide valuable information for tailoring treatment strategies to individual patient needs, potentially improving outcomes and helping to select therapies that are more likely to be effective. Discussing the results with your oncologist is crucial for understanding their implications and determining the best course of action.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo patient preparation is required. Ensure the FFPE tissue block is accompanied by a completed NGS Test Requisition Form (Form 40). Confirm with the laboratory before booking.
SampleFormalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue.
MethodologyMolecular genetic testing, specifically sequencing or mutation analysis of the NRAS gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only detects mutations in codons 12, 13, and 61 of the NRAS gene. It does not detect other mutations or genetic alterations. Results should be interpreted in the context of the patient's overall clinical picture. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The NRAS gene provides instructions for making a protein involved in cell growth and division. Mutations in this gene can contribute to the development of cancer.
Mutations in these specific locations (codons) of the NRAS gene are commonly found in certain cancers and can affect how the cancer responds to treatment.
A formalin-fixed paraffin-embedded (FFPE) tissue block containing tumor cells is required for this test.
Turnaround time varies. Please contact the laboratory for current estimates.
Results will indicate if specific mutations were detected. Your doctor will interpret these results in the context of your diagnosis and medical history.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Beta CTx Beta Crosslaps Collagen Type 1 C-Telopeptide Test

The Beta CTx test measures bone resorption markers to help assess bone health and osteoporosis risk.

Learn more →

Bcell Rearrangement Detection Test

The Bcell Rearrangement Detection Test helps diagnose leukemia by identifying genetic changes in B cells. It's a key tool for hematologists and oncologists.

Learn more →

Dpd Gene Mutations 5Fu Toxicity Detection Test

This genetic test identifies mutations in the DPD gene, helping predict the risk of severe side effects from the chemotherapy drug 5-fluorouracil (5FU).

Learn more →

Ganciclovir Resistance Detection Test

This test checks for genetic changes in the cytomegalovirus (CMV) that may make it resistant to the antiviral medication Ganciclovir. It helps guide treatment decisions, especially for patients with weakened immune systems.

Learn more →
Chat on WhatsApp